Abstract
This study aimed to assess whether standard-dose Betahistine (48 mg daily) exerts an effect upon the degree of endolymphatic hydrops in patients with Menière’s disease using a retrospective case series in the setting of a tertiary neurotology referral centre. In six patients with definite unilateral Menière’s disease, the degree of cochlear and vestibular endolymphatic hydrops was assessed before and after treatment with a standard dose of Betahistine (48 mg daily), using high-resolution 3 T MR imaging after intratympanic contrast medium application. The treatment duration was 3–7 months (mean 5 months), and the patients were followed-up for 6–29 months (mean 11 months). In the study cohort, the standard dose of Betahistine did not have an MR morphologically measurable beneficial effect on the degree of endolymphatic hydrops. The results indicated no effect of standard-dose Betahistine on endolymphatic hydrops found on high-resolution MR imaging. Possible explanations are: (1) insufficient dosage or duration of treatment with betahistine, (2) insufficient resolution of the MR imaging technique, and (3) insufficient length of follow-up. Further studies addressing these issues are warranted.
Similar content being viewed by others
References
Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. (1995) Otolaryngol Head Neck Surg 113:181-185
Merchant SN, Adams JC, Nadol JB Jr (2005) Pathophysiology of Meniere’s syndrome: are symptoms caused by endolymphatic hydrops? Otol Neurotol 26:74–81
Kim HH, Wiet RJ, Battista RA (2005) Trends in the diagnosis and the management of Meniere’s disease: results of a survey. Otolaryngol Head Neck Surg 132:722–726
Westhofen M (2009) Meniere’s disease: evidence and controversies. HNO 57:446–454
Smith WK, Sankar V, Pfleiderer AG (2005) A national survey amongst UK otolaryngologists regarding the treatment of Meniere’s disease. J Laryngol Otol 119:102–105
Timmerman H (1991) Histamine agonists and antagonists. Acta Otolaryngol Suppl 479:5–11
Arrang JM, Devaux B, Chodkiewicz JP et al (1988) H3-receptors control histamine release in human brain. J Neurochem 51:105–108
Martinez DM (1972) The effect of Serc (betahistine hydrochloride) on the circulation of the inner ear in experimental animals. Acta Otolaryngol Suppl 305:29–47
James AL, Burton MJ (2001) Betahistine for Meniere’s disease or syndrome. Cochrane Database Syst Rev (1):CD001873
Nakashima T, Naganawa S, Sugiura M et al (2007) Visualization of endolymphatic hydrops in patients with Meniere’s Disease. The Laryngoscope 117:415–420
Gurkov R, Flatz W, Louza J et al (2011) In vivo visualization of endolyphatic hydrops in patients with Meniere’s disease: correlation with audiovestibular function. Eur Arch Otorhinolaryngol 268:1743–1748
Louza J, Flatz W, Krause E, Gürkov R (2012) Short-term audiologic effect of intratympanic gadolinium contrast agent application in patients with Meniere’s disease. Am J Otolaryngol [Epub ahead of print]
Suzuki H, Teranishi M, Naganawa S et al (2011) Contrast-enhanced MRI of the inner ear after intratympanic injection of meglumine gadopentetate or gadodiamide hydrate. Acta Otolaryngol 131:130–135
Kato M, Teranishi M, Katayama N et al (2011) Association between endolymphatic hydrops as revealed by magnetic resonance imaging and caloric response. Otol Neurotol 32:1480–1485
Hornibrook J, Coates M, Goh A et al (2012) Magnetic resonance imaging for Meniere’s disease: correlation with tone burst electrocochleography. J Laryngol Otol 126:136–141
Horii A, Osaki Y, Kitahara T et al (2011) Endolymphatic hydrops in Meniere’s disease detected by MRI after intratympanic administration of gadolinium: comparison with sudden deafness. Acta Otolaryngol 131:602–609
Fang ZM, Chen X, Gu X, Liu Y, Zhang R, Cao DR, He HG (2012) A new magnetic resonance imaging scoring system for perilymphatic space appearance after intratympanic gadolinium injection, and its clinical application. J Laryngol Otol 126(5):454–459
Laurikainen E, Miller JM, Nuttall AL et al (1998) The vascular mechanism of action of betahistine in the inner ear of the guinea pig. Eur Arch Otorhinolaryngol 255:119–123
Laurikainen E, Miller JF, Pyykko I (2000) Betahistine effects on cochlear blood flow: from the laboratory to the clinic. Acta Otolaryngol Suppl 544:5–7
Strupp M, Hupert D, Frenzel C (2008) Long-term prophylactic treatment of attacks of vertigo in Meniere’s disease–comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol 128:520–524
Lezius F, Adrion C, Mansmann U et al (2011) High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meniere’s disease: a case series. Eur Arch Otorhinolaryngol 268:1237–1240
Acknowledgments
This study was supported by the Federal German Ministry of Education and Research (Grant no. 01EO0901). The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of interest
None of the authors have a conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gürkov, R., Flatz, W., Keeser, D. et al. Effect of standard-dose Betahistine on endolymphatic hydrops: an MRI pilot study. Eur Arch Otorhinolaryngol 270, 1231–1235 (2013). https://doi.org/10.1007/s00405-012-2087-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-012-2087-3